Ceftaroline - Revision history

Danbot: Add AntibioticDose SMW query table for dynamic indications by disease

2026-03-20T20:38:09Z

Add AntibioticDose SMW query table for dynamic indications by disease

@@ Línea 7: / Línea 7: @@
 * Pneumonia, Community-acquired: IV: 600 mg every 12 hours for 5 to 7 days
 * Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days
 ==Pediatric Dosing==
@@ Línea 23: / Línea 35: @@
 *** ≤ 33 kg: IV 12 mg/kg/dose every 8 hours
 *** > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours
 ==Special Populations==

2019-09-19T22:01:45Z

← Revisión anterior		Revisión del 22:01 19 sep 2019
Línea 1:		Línea 1:
	==General==		==General==
	*Type: Antibiotic, Cephalosporin (fifth generation)		*Type: [[Antibiotic]], [[Cephalosporin]] (fifth generation)
	*Dosage Forms: IV		*Dosage Forms: IV
	*Common Trade Names: Teflaro		*Common Trade Names: Teflaro
Línea 197:		Línea 197:
	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:ID]]
	Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.		Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.

2019-05-27T09:01:28Z

← Revisión anterior		Revisión del 09:01 27 may 2019
Línea 52:		Línea 52:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
			*[[C. diff]]
			*Elevated ALT/SGPT, hepatitis
			*[[Anaphylaxis]], hypersensitivity reaction
			*[[Seizure]]
			*[[Renal failure]]

	===Common===		===Common===
			*[[Nausea/vomiting]], [[diarrhea]]
			*[[Rash]]
			*[[Fever]]

	==Pharmacology==		==Pharmacology==

2019-04-01T19:28:44Z

Pharmacology

← Revisión anterior		Revisión del 19:28 1 abr 2019
Línea 57:		Línea 57:
	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life:
			** 1.6 ± 0.38 hours (single dose), 2.66 ± 0.4 hours (multiple doses)
	*Metabolism:		*Metabolism:
	*Excretion:		*Excretion:
			** Urine 88%, Feces 6%
	*Mechanism of Action:		*Mechanism of Action:
			** Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins

	==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==		==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==

2019-04-01T19:20:55Z

Pediatric Dosing

← Revisión anterior		Revisión del 19:20 1 abr 2019
Línea 9:		Línea 9:

	==Pediatric Dosing==		==Pediatric Dosing==
			* Cystic Fibrosis pulmonary exacerbation, MRSA:
			** Children ≥ 6 years old - IV 15 mg/kg/dose every 8 hours (max dose 600 mg/dose)

			* Pneumonia, community acquired:
			** ≥ 2 months - < 2 years age - IV 8 mg/kg/dose every 8 hours for 5-14 days
			** ≥ 2 years - < 18 years
			*** ≤ 33 kg: IV 12 mg/kg/dose every 8 hours for 5-14 days
			*** > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours for 5-14 days

			* Skin and skin structure infection:
			** ≥ 2 months - < 2 years age - IV 8 mg/kg/dose every 8 hours
			** ≥ 2 years - < 18 years
			*** ≤ 33 kg: IV 12 mg/kg/dose every 8 hours
			*** > 33 kg: IV 400 mg every 8 hours OR 600 mg every 12 hours

	==Special Populations==		==Special Populations==

2019-04-01T19:12:38Z

General

← Revisión anterior		Revisión del 19:12 1 abr 2019
Línea 1:		Línea 1:
	==General==		==General==
	*Type:		*Type: Antibiotic, Cephalosporin (fifth generation)
	*Dosage Forms:		*Dosage Forms: IV
	*Common Trade Names: Teflaro		*Common Trade Names: Teflaro

2019-04-01T19:10:43Z

Special Populations

← Revisión anterior		Revisión del 19:10 1 abr 2019
Línea 12:		Línea 12:
	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]:		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]:
			** Adverse events have been observed in animal studies
	*Lactation:		*Lactation:
			** Unknown if excreted in breast milk. Manufacturer recommends to use caution when giving to nursing women.
	*Renal Dosing		*Renal Dosing
	**Adult		**Adult
Línea 24:		Línea 26:
	**** CrCl > 50 mL/minute/1.73 m²: No adjustment necessary		**** CrCl > 50 mL/minute/1.73 m²: No adjustment necessary
	**** CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary		**** CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary
			*** ≥ 18 years of age - same as adult dosing
	*Hepatic Dosing		*Hepatic Dosing
	**Adult		**Adult
			*** No dosage adjustment in manufacturer's labeling. Has not been studied.
	**Pediatric		**Pediatric
			*** No dosage adjustment in manufacturer's labeling. Has not been studied.

	==Contraindications==		==Contraindications==

2019-04-01T19:04:36Z

Special Populations

← Revisión anterior		Revisión del 19:04 1 abr 2019
Línea 21:		Línea 21:
	*** ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days		*** ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days
	**Pediatric		**Pediatric
			*** ≥ 2 months to < 18 years of age
			**** CrCl > 50 mL/minute/1.73 m²: No adjustment necessary
			**** CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary
	*Hepatic Dosing		*Hepatic Dosing
	**Adult		**Adult

2019-04-01T19:00:44Z

Special Populations

← Revisión anterior		Revisión del 19:00 1 abr 2019
Línea 15:		Línea 15:
	*Renal Dosing		*Renal Dosing
	**Adult		**Adult
			*** CrCl > 50 mL/minute: No dosage adjustment necessary
			*** CrCl > 30 to ≤ 50 mL/minute: 400 mg every 12 hours
			*** CrCl ≥ 15 to ≤ 30 mL/minute: 300 mg every 12 hours
			*** CrCl < 15 mL/minute: 200 mg every 12 hours
			*** ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days
	**Pediatric		**Pediatric
	*Hepatic Dosing		*Hepatic Dosing

2019-04-01T18:53:26Z

References

← Revisión anterior		Revisión del 18:53 1 abr 2019
Línea 160:		Línea 160:
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.